Strong earnings guidance and recent product accolades bolster Medtronic's valuation; the stock has broken above its 200‑day SMA, signaling bullish momentum. Technical support at $70.50 and resistance near $80.00 paint a positive trajectory.

TIME’s recognition of Medtronic’s devices fuels investor enthusiasm and refines the narrative around longevity in the medical device sector; the broader trends in digital health are face‑turning upward. Analysts anticipate sustained demand, keeping the consensus bullish.

MiniMed’s spin‑off introduces short‑term uncertainty as the two entities re‑allocate R&D resources, potentially impacting earnings guidance. Long‑term outlook remains neutral until post‑separation integration stabilizes.

Volume‑weighted average price over 30 days has risen 5% and RSI is showing bullish divergence; support at $68 and resistance near $78 suggest upward breakout potential. On the downside, the price has breached the 50‑day EMA, reinforcing momentum.